


Ellerston Australian Emerging Leaders Fund



Monthly Newsletter, April 2022

Investment Objective

To provide investors with long term capital growth by investing in a portfolio of quality Australian & New Zealand companies. The Fund aims to outperform the S&P/ASX Small Ordinaries Accumulation Index over the medium to long term.

Investment Strategy

The Fund employs an active, research-driven investment approach which seeks to identify a portfolio of smaller company Securities with the aim of delivering superior returns to the Benchmark over time. The Fund will invest in companies that are believed to have the potential to deliver significant upside over the medium term and where there is a reasonable margin of safety to mitigate the downside risk. Positions are actively managed within the Fund.

Key Information

Strategy Inception ^^	13 August 2021
Portfolio Manager	David Keelan & Alexandra Clarke
Application Price	\$0.9412
Net Asset Value	\$0.9389
Redemption Price	\$0.9366
Liquidity	Daily
No Stocks	41
Management Fee	1.10% p.a.
Performance Fee	20%
Buy/Sell Spread	0.25% on application 0.25% on redemption

Performance Summary

Performance	1 Month	3 Months	6 Months	1 Year	3 Years (p.a.)	Since Inception (p.a.)^^
Net^	-1.98%	1.94%	-9.50%	-	-	-6.11%
Benchmark*	-1.50%	3.68%	-4.61%	-	-	-4.25%
Alpha	-0.49%	-1.73%	-4.90%	-	-	-1.86%

^ The net return figure is calculated after fees & expenses. Past performance is not a reliable indication of future performance
* S&P/ASX Small Ordinaries Accumulation Index

COMMENTARY

The Ellerston Australian Emerging Leaders Fund underperformed the Small Ordinaries Accumulation Index by 0.49% in April. April was another challenging month for the equities markets with ongoing concerns around inflation, interest rates, COVID lockdowns in China and continuing Ukraine / Russia tension impacting sentiment. Closer to home we also had the starters gun go off on the upcoming Federal Election (called for the 21 May) with both parties releasing a range of new potential policies. While Australian markets were down for the month, they held up relatively better than US equities where we saw the S&P 500 down 8.7% and the NASDAQ down 13.2%. Against this macro backdrop as expected more defensive sectors outperformed while Information Technology sector was worst hit. Once again Small Resources (+0.3%) outperformed Small Industrials (-2.1%) pushed higher by the coal names.

During these volatile markets we continue to stick to our process of looking for stocks which provide a 3 to 1 risk return. While the market has been pushed higher by an exceptionally strong resource sector, it has meant that small industrials have been marked down aggressively. Small industrials are our bread and butter and this market sell off is creating opportunities to increase our weights in names we already hold and open new positions at highly attractive prices.

Turning to stocks, two names that had quality updates in the month were Generation Development Group (GDG AU) and Aroa Biosurgery (ARX AU).

Generation Development Group (GDG AU) was one of our stronger performers during April, putting on almost 10%. The company released a solid March quarterly update, which emphasised the ongoing momentum in the core Investment Bond business and Lonsec, despite being a seasonally quieter period. We think the highlight of the period was the launch of the new market-linked lifetime annuity product. While still early days, we are excited about this opportunity, as it will give the company exposure to post-retirement superannuation market which is expected to exceed \$1 trillion in assets in the coming years. With a well-thought-out product, a strong brand in the industry and a sales network which is firing on all cylinders, we believe GDG is well placed to capitalise on this enormous opportunity.

Aroa Biosurgery (ARX AU) is a NZ based soft tissue regeneration company founded in 2008. ARX develops and manufactures medical devices for hernia repair, wound healing, soft tissue reinforcement and reconstructive surgery. All of ARX's products feature a proprietary extracellular matrix (ECM) biomaterial derived from ovine (sheep) forestomach. ARX had a strong month, closing +14% on the back of its 4Q22 update. The update revealed ARX achieved above the top-end of its upgraded revenue guidance, delivering total revenue of NZ\$39m (product sales up 81% year on year). The business continues to invest in its manufacturing and sales team and has a healthy NZ\$56m cash position. Despite recent volatility in valuations for the healthcare sector, we believe ARX is well placed to deliver continued growth into FY23 and management has built a strong track record of execution since listing.


PORTFOLIO CHARACTERISTICS

Key Portfolio Metrics

FY22e	Fund	Benchmark
Price/Earnings	18.6x	17.0x
Dividend Yield	1.9%	3.3%
Net Debt/EBITDA	0.1x	1.1x


Source: Ellerston Capital.

Market Capitalisation



Source: Ellerston Capital.

Sector Allocation



Source: Ellerston Capital.

Contact Us

Sydney

Level 11, 179 Elizabeth Street,
Sydney, NSW 2000
+612 9021 7701
info@ellerstoncapital.com

Find out more

Should investors have any questions or queries regarding the Fund, please contact our Investor Relations team on 02 9021 7701 or info@ellerstoncapital.com or visit us at ellerstoncapital.com

All holding enquiries should be directed to our register, Link Market Services on 1800 992 149 or ellerston@linkmarketservices.com.au

This report has been prepared by Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000, as the responsible entity of the Ellerston Australian Emerging Leaders Fund ARSN 647 979 333 without taking account the objectives, financial situation or needs of individuals. Before making an investment decision about the Fund persons should read the Fund's Product Disclosure Statement and Target Market Determination (TMD) which can be obtained from the Manager's website www.ellerstoncapital.com or by contacting info@ellerstoncapital.com and obtain advice from an appropriate financial adviser. Units in the Fund are issued by Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000. This information is current as at the date on the first page.

This material has been prepared based on information believed to be accurate at the time of publication. Assumptions and estimates may have been made which may prove not to be accurate. Ellerston Capital undertakes no responsibility to correct any such inaccuracy. Subsequent changes in circumstances may occur at any time and may impact the accuracy of the information. To the full extent permitted by law, none of Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000, or any member of the Ellerston Capital Limited Group of companies makes any warranty as to the accuracy or completeness of the information in this newsletter and disclaims all liability that may arise due to any information contained in this newsletter being inaccurate, unreliable or incomplete. Past performance is not a reliable indicator of future performance.